Pathobiological mechanisms underlying metabolic syndrome (MetS) in chronic obstructive pulmonary disease (COPD): clinical significance and therapeutic strategies
| Autor: | Steven Bozinovski, Ross Vlahos, Stavros Selemidis, Stanley M H Chan |
|---|---|
| Rok vydání: | 2019 |
| Předmět: |
0301 basic medicine
obesity immunometabolism AECOPD Acute exacerbation of chronic obstructive pulmonary disease Comorbidity Disease GOLD Global initiative for chronic obstructive lung disease VLDL Very low density lipoprotein Pulmonary Disease Chronic Obstructive FEV1 Forced expiratory volume in the first second 0302 clinical medicine CVD Cardiovascular disease Pharmacology (medical) Wasting Cause of death Metabolic Syndrome COPD oxidants Smoking HIF Hypoxia-inducible factor NAFLD Non-alcoholic fatty liver disease 3. Good health 030220 oncology & carcinogenesis CRP C-reactive protein medicine.symptom medicine.medical_specialty COPD Chronic obstructive pulmonary disease Article COPD comorbidities 03 medical and health sciences IL-8 Interleukin 8 AMPK Adenosine monophosphate-activated protein kinase medicine Animals Humans Clinical significance MetS Metabolic syndrome Intensive care medicine Disease burden TNF-α Tumour necrosis factor-α metabolic dysregulation Pharmacology business.industry medicine.disease respiratory tract diseases 030104 developmental biology LDL Low density lipoprotein AM Alveolar macrophages Metabolic syndrome business ROS Reactive oxygen species SREBP-1c Sterol response element binding protein-1c |
| Zdroj: | Pharmacology & Therapeutics |
| ISSN: | 0163-7258 |
| DOI: | 10.1016/j.pharmthera.2019.02.013 |
| Popis: | Chronic obstructive pulmonary disease (COPD) is a major incurable global health burden and is currently the 4th largest cause of death in the world. Importantly, much of the disease burden and health care utilisation in COPD is associated with the management of its comorbidities (e.g. skeletal muscle wasting, ischemic heart disease, cognitive dysfunction) and infective viral and bacterial acute exacerbations (AECOPD). Current pharmacological treatments for COPD are relatively ineffective and the development of effective therapies has been severely hampered by the lack of understanding of the mechanisms and mediators underlying COPD. Since comorbidities have a tremendous impact on the prognosis and severity of COPD, the 2015 American Thoracic Society/European Respiratory Society (ATS/ERS) Research Statement on COPD urgently called for studies to elucidate the pathobiological mechanisms linking COPD to its comorbidities. It is now emerging that up to 50% of COPD patients have metabolic syndrome (MetS) as a comorbidity. It is currently not clear whether metabolic syndrome is an independent co-existing condition or a direct consequence of the progressive lung pathology in COPD patients. As MetS has important clinical implications on COPD outcomes, identification of disease mechanisms linking COPD to MetS is the key to effective therapy. In this comprehensive review, we discuss the potential mechanisms linking MetS to COPD and hence plausible therapeutic strategies to treat this debilitating comorbidity of COPD. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full Text from ScienceDirect